Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2015, Pages 230-239

  Chandorkar, Gurudatt ^a   Xiao, Alan ^a   Mouksassi, Mohamad Samer ^b   Hershberger, Ellie ^a   Krishna, Gopal ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b PHARSIGHT CORPORATION   (United States)

Author keywords

ceftolozane tazobactam; complicated intra abdominal infections; complicated urinary tract infections; population pharmacokinetics; lactam antibacterials

Indexed keywords

CEFTOLOZANE; CREATININE; TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; ETHNICITY; FEMALE; HUMAN; KIDNEY FUNCTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY TRACT INFECTION; VITAL CAPACITY; VOLUME OF DISTRIBUTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PENICILLANIC ACID; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 84921018804     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.395     Document Type: Article

References (25)

1. Sader HS, Rhomberg PR, Farrell DJ, Jones RN,. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011; 55 (5): 2390-2394.
2. Sader HS, Farrell DJ, Flamm RK, Jones RN,. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014; 69 (3): 266-277.
3. Farrell DJ, Flamm RK, Sader HS, Jones RN,. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother. 2013; 57 (12): 6305-6310.
4. Titelman E, Karlsson IM, Ge Y, Giske CG,. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011; 70 (1): 137-141.
5. Moya B, Zamorano L, Juan C, Ge Y, Oliver A,. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54 (9): 3933-3937.
6. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K,. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007; 30 (5): 443-445.
7. Craig WA, Andes DR,. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013; 57 (4): 1577-1582.
8. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G,. Impact of renal function on the pharmacokinetics and safety of ceftolozane/tazobactam. Antimicrob Agents Chemother. 2014; 58 (4): 2249-2255.
9. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I,. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56 (6): 3086-3091.
10. VanScoy B, Mendes RE, Nicasio AM, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013; 57 (6): 2809-2814.
11. Committee for Medicinal Products for Human Use (CHMP),. Guideline on reporting the results of population pharmacokinetic analyses. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003067.pdf Accessed August 12, 2013.
12. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Exposure-response relationships: study design, data analysis, and regulatory applications. FDA Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf Accessed August 12, 2013.
13. Ge Y, Whitehouse MJ, Friedland I, Talbot GH,. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010; 54 (8): 3427-3431.
14. Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O,. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012; 67 (10): 2463-2469.
15. Miller B, Chandorkar G, Umeh O, Friedland I, Hershberger E,. Safety and pharmacokinetics of intravenous ceftolozane/tazobactam 3 g every 8 hours and cumulative fraction of response in plasma and epithelial lining fluid in a simulated ventilator associated pneumonia population. Presented at: 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012); September 9-12, 2012; San Francisco, CA. Poster A-624.
16. Umeh O, Cebrik D, Friedland IR,. A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 and intravenous ceftazidime in complicated urinary tract infection. Presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010); September 12-15, 2010; Boston, MA. Poster L1-361A.
17. Lucasti C, Hershberger E, Miller B, et al. A multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane/tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58 (9): 5350-5357.
18. Fenneteau F, Kassir N, Mouksassi MS, Merdjan H, Marier JF, Hershberger E,. Population PK/PD modeling and simulations of a fixed-dose combination of CXA-101 and tazobactam to optimize dosing strategies in renally impaired patients with complicated urinary tract infection. Presented at: 3rd Biennial American Conference on Pharmacometrics (ACoP 2011); April 3-6, 2011; Coronado, CA. Poster.
19. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
20. Yano Y, Beal SL, Sheiner LB,. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001; 28 (2): 171-192.
21. Adnan S, Paterson DL, Lipman J, et al. Pharmacokinetics of β-lactam antibiotics in patients with intra-abdominal disease: a structured review. Surg Infect (Larchmt). 2012; 13 (1): 9-17.
22. VanScoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother. 2013; 57 (12): 5924-5930.
23. Concordet D, Leger F, Ane C,. Population PK/PD analysis. In:, Chow SC, ed., Encyclopedia of Biopharmaceutical Statistics. New York, NY: Marcel Dekker, Inc. 2004.
24. Goncalves-Pereira J, Povoa P,. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011; 15 (5): R206.
25. Udy AA, Roberts JA, Lipman J,. How should we dose antibiotics for pneumonia in the ICU? Curr Opin Infect Dis. 2013; 26 (2): 189-195.